Neuroscience
We are building a world-class pipeline driven by innovation that we hope will lead to transformative therapies for a diverse population of patients with neuropsychiatric, neurodegenerative and neurological disorders. Through scientific advancements, a broad range of expertise, and strategic partnerships, we aim to fundamentally change how these disorders are treated and make a real difference, not just for patients, but also for society.
We are determined to continue to increase our understanding of nervous system disorders by supporting and engaging with patients, through open dialogue and innovative treatments.
We cannot look at neuroscience through the lens of science alone. Each person’s experience of a nervous system disease is uniquely influenced by personal, medical, environmental and social factors.[4] It is essential to work in partnership with the patient community to drive change, innovation and transformation, and we are committed to ensuring the success of our collaborations.
Today, we are committed to maintaining innovative Research and Development (R&D) that solves for unmet needs across nervous system disorders.
Our alliances take many forms, but our goal is always the same: to advance scientific research and deliver solutions that provide value to patients, physicians and society. We actively pursue new ways of collaborating in our core areas of interest and seek out like-minded health and technology companies to partner with.
Our extensive research and innovations aim to improve the quality of care for millions of people with neurological conditions. We’ve equipped ourselves with the knowledge, tools and technology to expand our focus into the full range of psychosis spectrum disorders and mood dysregulation, and by leveraging shared pathology across disease areas to broaden therapeutic opportunities and develop innovations for populations with high unmet needs - such as, for instance in neurodegenerative and neurological disorders. We’re motivated by making a real difference for not just patients, but for society as a whole.”
References
[1]Deuschl G, et al. The burden of neurological diseases in Europe: An analysis for the Global Burden of Disease Study 2017. Lancet Public Health. 2020;5(10):E551-E567.
[2]Open Access Government 2019. Tackling the growing burden of brain disorders in Europe. Available at: https://www.openaccessgovernment.org/brain-disorders-in-europe/72909/. Last accessed July 2023.
[3]GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet 2018;392:1789-1858.
[4]PsychGuides.com. Neurological Problem Symptoms, Causes and Effects. Available at: https://www.psychguides.com/neurological-disorders/. Last accessed July 2023.
[5]WHO. Depression and other common mental disorders. Available at: WHO-MSD-MER-2017.2-eng.pdf Last accessed July 2023.
[6]WHO. Fact sheets. Depression. Available at
https://www.who.int/news-room/fact-sheets/detail/depression. Last accessed July 2023.
[7]Machado-Viera R, et al. The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments. Pharmaceuticals. 2010;3(1):19–41.
[8]Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges and future directions. Patient Pref Adherence. 2012;6:369–388.
[9]Demyttenaere K & Van Duppen D. The Impact of (the Concept of) Treatment-Resistant Depression: An Opinion Review. Int J Neuropsychopharmacol 2019;22(2):85–92.
[10]Rush AJ, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-17.
[11]Heerlein K, Perugi G, Otte C, et al. Real-world evidence from a European cohort study of patients with treatment resistant depression: Treatment patterns and clinical outcomes. J Affect Disord. 2021;290:334-344.
CP-459038
September 2024